Acyl-CoA synthetase-4, a new regulator of mTOR and a potential therapeutic target for enhanced estrogen receptor function in receptor-positive and -negative breast cancer
Although the role of acyl-CoA synthetase 4 (ACSL4) in mediating an aggressive phenotype is well accepted, there is little evidence as to the early steps through which ACSL4 increases tumor growth and progression. In this study, and by means of the stable transfection of MCF-7 cells with ACSL4 using...
Saved in:
Published in | Oncotarget Vol. 6; no. 40; pp. 42632 - 42650 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Impact Journals LLC
15.12.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Although the role of acyl-CoA synthetase 4 (ACSL4) in mediating an aggressive phenotype is well accepted, there is little evidence as to the early steps through which ACSL4 increases tumor growth and progression. In this study, and by means of the stable transfection of MCF-7 cells with ACSL4 using the tetracycline Tet-Off system (MCF-7 Tet-Off/ACSL4), we identify the mTOR pathway as one of the main specific signatures of ACSL4 expression and demonstrate the partial involvement of the lipoxygenase pathway in the activation of mTOR. The specificity of ACSL4 action on mTOR signaling is also determined by doxycycline inhibition of ACSL4 expression in MCF-7 Tet-Off/ACSL4 cells, by the expression of ACSL4 in the non-aggressive T47D breast cancer cell line and by knocking down this enzyme expression in the MDA-MB-231 breast cancer cells, which constitutively express ACSL4. ACSL4 regulates components of the two complexes of the mTOR pathway (mTORC1/2), along with upstream regulators and substrates.We show that mTOR inhibitor rapamycin and ACSL4 inhibitor rosiglitazone can act in combination to inhibit cell growth. In addition, we demonstrate a synergistic effect on cell growth inhibition by the combination of rosiglitazone and tamoxifen, an estrogen receptor α (ERα) inhibitor. Remarkably, this synergistic effect is also evident in the triple negative MDA-MB-231 cells in vitro and in vivo.These results suggest that ACSL4 could be a target to restore tumor hormone dependence in tumors with poor prognosis for disease-free and overall survival, in which no effective specifically targeted therapy is readily available. |
---|---|
AbstractList | Although the role of acyl-CoA synthetase 4 (ACSL4) in mediating an aggressive phenotype is well accepted, there is little evidence as to the early steps through which ACSL4 increases tumor growth and progression. In this study, and by means of the stable transfection of MCF-7 cells with ACSL4 using the tetracycline Tet-Off system (MCF-7 Tet-Off/ACSL4), we identify the mTOR pathway as one of the main specific signatures of ACSL4 expression and demonstrate the partial involvement of the lipoxygenase pathway in the activation of mTOR. The specificity of ACSL4 action on mTOR signaling is also determined by doxycycline inhibition of ACSL4 expression in MCF-7 Tet-Off/ACSL4 cells, by the expression of ACSL4 in the non-aggressive T47D breast cancer cell line and by knocking down this enzyme expression in the MDA-MB-231 breast cancer cells, which constitutively express ACSL4. ACSL4 regulates components of the two complexes of the mTOR pathway (mTORC1/2), along with upstream regulators and substrates.We show that mTOR inhibitor rapamycin and ACSL4 inhibitor rosiglitazone can act in combination to inhibit cell growth. In addition, we demonstrate a synergistic effect on cell growth inhibition by the combination of rosiglitazone and tamoxifen, an estrogen receptor α (ERα) inhibitor. Remarkably, this synergistic effect is also evident in the triple negative MDA-MB-231 cells in vitro and in vivo.These results suggest that ACSL4 could be a target to restore tumor hormone dependence in tumors with poor prognosis for disease-free and overall survival, in which no effective specifically targeted therapy is readily available. Although the role of acyl-CoA synthetase 4 (ACSL4) in mediating an aggressive phenotype is well accepted, there is little evidence as to the early steps through which ACSL4 increases tumor growth and progression. In this study, and by means of the stable transfection of MCF-7 cells with ACSL4 using the tetracycline Tet-Off system (MCF-7 Tet-Off/ACSL4), we identify the mTOR pathway as one of the main specific signatures of ACSL4 expression and demonstrate the partial involvement of the lipoxygenase pathway in the activation of mTOR. The specificity of ACSL4 action on mTOR signaling is also determined by doxycycline inhibition of ACSL4 expression in MCF-7 Tet-Off/ACSL4 cells, by the expression of ACSL4 in the non-aggressive T47D breast cancer cell line and by knocking down this enzyme expression in the MDA-MB-231 breast cancer cells, which constitutively express ACSL4. ACSL4 regulates components of the two complexes of the mTOR pathway (mTORC1/2), along with upstream regulators and substrates. We show that mTOR inhibitor rapamycin and ACSL4 inhibitor rosiglitazone can act in combination to inhibit cell growth. In addition, we demonstrate a synergistic effect on cell growth inhibition by the combination of rosiglitazone and tamoxifen, an estrogen receptor α (ERα) inhibitor. Remarkably, this synergistic effect is also evident in the triple negative MDA-MB-231 cells in vitro and in vivo . These results suggest that ACSL4 could be a target to restore tumor hormone dependence in tumors with poor prognosis for disease-free and overall survival, in which no effective specifically targeted therapy is readily available. |
Author | Orlando, Ulises D Dattilo, Melina A Podesta, Ernesto J Castillo, Ana F Maloberti, Paula M Solano, Angela R |
AuthorAffiliation | 1 Biomedical Research Institute, INBIOMED, Department of Biochemistry, School of Medicine, University of Buenos Aires, CABA, Buenos Aires, Argentina |
AuthorAffiliation_xml | – name: 1 Biomedical Research Institute, INBIOMED, Department of Biochemistry, School of Medicine, University of Buenos Aires, CABA, Buenos Aires, Argentina |
Author_xml | – sequence: 1 givenname: Ulises D surname: Orlando fullname: Orlando, Ulises D organization: Biomedical Research Institute, INBIOMED, Department of Biochemistry, School of Medicine, University of Buenos Aires, CABA, Buenos Aires, Argentina – sequence: 2 givenname: Ana F surname: Castillo fullname: Castillo, Ana F organization: Biomedical Research Institute, INBIOMED, Department of Biochemistry, School of Medicine, University of Buenos Aires, CABA, Buenos Aires, Argentina – sequence: 3 givenname: Melina A surname: Dattilo fullname: Dattilo, Melina A organization: Biomedical Research Institute, INBIOMED, Department of Biochemistry, School of Medicine, University of Buenos Aires, CABA, Buenos Aires, Argentina – sequence: 4 givenname: Angela R surname: Solano fullname: Solano, Angela R organization: Biomedical Research Institute, INBIOMED, Department of Biochemistry, School of Medicine, University of Buenos Aires, CABA, Buenos Aires, Argentina – sequence: 5 givenname: Paula M surname: Maloberti fullname: Maloberti, Paula M organization: Biomedical Research Institute, INBIOMED, Department of Biochemistry, School of Medicine, University of Buenos Aires, CABA, Buenos Aires, Argentina – sequence: 6 givenname: Ernesto J surname: Podesta fullname: Podesta, Ernesto J organization: Biomedical Research Institute, INBIOMED, Department of Biochemistry, School of Medicine, University of Buenos Aires, CABA, Buenos Aires, Argentina |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26536660$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkU1v1DAQhi1UREvpnRPykQMp8WfiC9JqRQtSpUqonC3HmWSNsnawnVb7l_iVeHdLW3yxxzPv4_G8b9GJDx4Qek_qS9JKRj8Hb0M2cYR8KVpKX6EzoriqqBDs5MX5FF2k9KsuS_CmpeoNOqVSMCllfYb-rOxuqtZhhdPO5w1kk6Din7DBHh5whHGZTA4RhwFv725_YOP7kptDBp-dmXCRRDPDkp3Fx17wUMrBb4y30GNIOYYRfEFZmPekYfE2u-Cxe76s5pBcdvdw4FceRnOIuggmZWz3rPgOvR7MlODicT9HP6--3q2_VTe319_Xq5vKMiVzpUwPHbcD71Ur-x5ox7umLfPhNTGqVqonjNtOECbrzrZ2UECbTlpB2oGqlrBz9OXInZduC70tP41m0nN0WxN3Ohin_894t9FjuNe8kQ0XqgA-PgJi-L2UCeitSxamyXgIS9KkEbxuBWO0lNbHUhtDShGGp2dIrQ8u62eX9d7lIvnwsr0nwT9P2V_6Mqxi |
CitedBy_id | crossref_primary_10_1016_j_bcp_2021_114718 crossref_primary_10_1158_1541_7786_MCR_20_0379 crossref_primary_10_1016_j_jsbmb_2020_105792 crossref_primary_10_1016_j_bmcl_2021_128486 crossref_primary_10_3390_ijms232214334 crossref_primary_10_1210_endocr_bqac170 crossref_primary_10_18632_oncotarget_28453 crossref_primary_10_3892_ol_2018_8843 crossref_primary_10_1111_jcmm_13135 crossref_primary_10_1186_s40364_020_00230_3 crossref_primary_10_3390_ijms242417279 crossref_primary_10_1016_j_bcp_2018_11_005 crossref_primary_10_1038_s41598_019_46776_7 crossref_primary_10_1093_carcin_bgx020 crossref_primary_10_1155_2022_6495301 crossref_primary_10_3892_or_2017_5610 crossref_primary_10_1007_s00018_020_03679_5 crossref_primary_10_3390_metabo12040350 crossref_primary_10_1016_j_chembiol_2022_06_004 crossref_primary_10_1038_nchembio_2239 crossref_primary_10_18632_aging_103092 crossref_primary_10_1038_s41598_024_57000_6 crossref_primary_10_3389_fgene_2022_812674 crossref_primary_10_1007_s40139_017_0139_5 crossref_primary_10_1002_cmdc_201700703 crossref_primary_10_3390_cancers13215348 crossref_primary_10_3390_ijms241914857 crossref_primary_10_1016_j_cbpb_2022_110737 crossref_primary_10_1007_s11033_023_08868_6 crossref_primary_10_1155_2021_9999612 crossref_primary_10_1016_j_omtn_2019_07_011 crossref_primary_10_1016_j_heliyon_2024_e30639 crossref_primary_10_1002_bies_202100093 crossref_primary_10_3390_cancers16071313 crossref_primary_10_3389_fncel_2020_577403 crossref_primary_10_18632_oncotarget_15494 crossref_primary_10_3389_fvets_2023_1296208 crossref_primary_10_18632_oncotarget_12284 |
Cites_doi | 10.1056/NEJMra055323 10.1016/j.jss.2006.07.003 10.1016/j.tibs.2003.12.004 10.1194/jlr.M015552 10.3892/mmr_00000131 10.1186/1476-4598-2-10 10.1007/s10555-007-9096-5 10.1074/jbc.M010793200 10.1016/j.cell.2012.03.017 10.1038/nrm2672 10.1523/JNEUROSCI.3547-13.2014 10.1038/sj.onc.1204091 10.1073/pnas.191379498 10.1158/1535-7163.MCT-05-0347 10.1016/j.ydbio.2011.02.030 10.1042/bj3590001 10.1128/MCB.21.24.8671-8683.2001 10.1158/1078-0432.CCR-03-0043 10.1016/j.molcel.2008.03.003 10.1111/j.1349-7006.2003.tb01458.x 10.1074/jbc.M610023200 10.1074/jbc.M508361200 10.1128/MCB.26.1.63-76.2006 10.1083/jcb.200403069 10.1126/science.1106148 10.1091/mbc.e05-04-0342 10.1038/sj.onc.1209889 10.1016/j.devcel.2013.11.011 10.1038/onc.2010.139 10.1038/nrc2389 10.1038/onc.2012.47 10.2174/187152010794728648 10.1371/journal.pone.0040794 10.1016/j.yexcr.2008.08.018 10.1593/tlo.09202 10.1158/1541-7786.MCR-09-0409 10.1371/journal.pone.0015540 10.1371/journal.pone.0077060 10.2337/db06-0267 10.1016/j.cell.2006.06.055 |
ContentType | Journal Article |
Copyright | Copyright: © 2015 Orlando et al. 2015 |
Copyright_xml | – notice: Copyright: © 2015 Orlando et al. 2015 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.18632/oncotarget.5822 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1949-2553 |
EndPage | 42650 |
ExternalDocumentID | 10_18632_oncotarget_5822 26536660 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 53G ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CGR CUY CVF DIK ECM EIF FRJ GX1 HYE KQ8 M48 M~E NPM OK1 PGMZT RPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c396t-9adeb4cf4d986dde2b4b78822401a9099d134cb51360bc8cf9e27b6c518f29813 |
IEDL.DBID | RPM |
ISSN | 1949-2553 |
IngestDate | Tue Sep 17 21:15:33 EDT 2024 Fri Aug 16 21:18:37 EDT 2024 Fri Dec 06 04:48:58 EST 2024 Sat Sep 28 08:01:20 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 40 |
Keywords | arachidonic acid cancer gene expression tamoxifen cell signaling |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c396t-9adeb4cf4d986dde2b4b78822401a9099d134cb51360bc8cf9e27b6c518f29813 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767459/ |
PMID | 26536660 |
PQID | 1754085332 |
PQPubID | 23479 |
PageCount | 19 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4767459 proquest_miscellaneous_1754085332 crossref_primary_10_18632_oncotarget_5822 pubmed_primary_26536660 |
PublicationCentury | 2000 |
PublicationDate | 2015-12-15 |
PublicationDateYYYYMMDD | 2015-12-15 |
PublicationDate_xml | – month: 12 year: 2015 text: 2015-12-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Oncotarget |
PublicationTitleAlternate | Oncotarget |
PublicationYear | 2015 |
Publisher | Impact Journals LLC |
Publisher_xml | – name: Impact Journals LLC |
References | 20501647 - Mol Cancer Res. 2010 Jun;8(6):896-906 11526226 - Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10031-3 14871980 - Clin Cancer Res. 2004 Feb 1;10(3):1013-23 18432252 - Nat Rev Cancer. 2008 May;8(5):387-98 11563964 - Biochem J. 2001 Oct 1;359(Pt 1):1-16 11426655 - Oncogene. 2000 Dec 27;19(56):6680-6 20360933 - Transl Oncol. 2010 Apr;3(2):91-8 19339977 - Nat Rev Mol Cell Biol. 2009 May;10(5):307-18 17763971 - Cancer Metastasis Rev. 2007 Dec;26(3-4):525-34 24553921 - J Neurosci. 2014 Feb 19;34(8):2785-96 17041623 - Oncogene. 2006 Oct 16;25(48):6373-83 12824887 - Cancer Sci. 2003 May;94(5):421-4 11319222 - J Biol Chem. 2001 Jul 6;276(27):24667-73 16354680 - Mol Cell Biol. 2006 Jan;26(1):63-76 15249583 - J Cell Biol. 2004 Jul 19;166(2):213-23 24332754 - Dev Cell. 2013 Dec 23;27(6):635-47 18439900 - Mol Cell. 2008 Apr 25;30(2):214-26 22349822 - Oncogene. 2013 Jan 10;32(2):160-70 22808264 - PLoS One. 2012;7(7):e40794 21085606 - PLoS One. 2010;5(11):e15540 16221682 - J Biol Chem. 2005 Dec 9;280(49):40406-16 18804105 - Exp Cell Res. 2008 Nov 1;314(18):3340-55 17259370 - Diabetes. 2007 Apr;56(4):1143-52 16505118 - Mol Cancer Ther. 2006 Feb;5(2):430-7 17074751 - J Biol Chem. 2006 Dec 22;281(51):39128-34 22438566 - Cold Spring Harb Perspect Biol. 2012 May;4(5). pii: a008052. doi: 10.1101/cshperspect.a008052 24155918 - PLoS One. 2013;8(10):e77060 17109887 - J Surg Res. 2007 Mar;138(1):37-44 11731423 - Cancer Res. 2001 Dec 1;61(23):8429-34 11713299 - Mol Cell Biol. 2001 Dec;21(24):8671-83 21214510 - Anticancer Agents Med Chem. 2010 Dec;10(10):735-41 22500797 - Cell. 2012 Apr 13;149(2):274-93 21385576 - Dev Biol. 2011 May 15;353(2):259-65 20418915 - Oncogene. 2010 Jul 1;29(26):3733-44 12575899 - Mol Cancer. 2003 Jan 7;2:10 17005952 - N Engl J Med. 2006 Sep 28;355(13):1345-56 19016759 - Cancer Sci. 2008 Oct;99(10):1992-2003 12734009 - Genome Biol. 2003;4(5):P3 21903867 - J Lipid Res. 2011 Nov;52(11):1936-48 15718470 - Science. 2005 Feb 18;307(5712):1098-101 21475860 - Mol Med Rep. 2009 Jul-Aug;2(4):527-31 16079174 - Mol Biol Cell. 2005 Oct;16(10):4572-83 15102436 - Trends Biochem Sci. 2004 Feb;29(2):95-102 16959574 - Cell. 2006 Sep 8;126(5):955-68 Cornejo Maciel (47) 2011; 52 Rowinsky (26) 2000; 19 Blenis (13) 2009; 10 46 Sarbassov dos (15) 2010; 8 Kandror (23) 2006; 26 25 Kim (8) 2003; 94 Shaw (16) 2008; 30 Monaco (5) 2013; 8 Cohen (21) 2001; 359 Podesta (4) 2012; 7 Johnson (20) 2004; 29 Wang (38) 2011; 353 Golubovskaya (24) 2010; 10 Zhang (39) 2014; 34 Monaco (10) 2013; 10 Kimball (34) 2006; 281 Polakis (35); 4 Stafforini (9) 2010; 3 Lamb (22) 2004; 166 Birchmeier (36) 2008; 8 11 Podesta (6) 2010; 5 Guertin (17) 2010; 29 Farber (37) 2013; 27 Prescott (7) 2001; 61 Salazar (43) 2008; 314 Adrian (3) 2003; 2 Kohn (27) 2001; 98 Bai (42) 2013; 32 Cohen (31) 2008; 99 Firtel (41) 2005; 16 Meyuhas (14) 2001; 21 Sabatini (33) 2006; 25 Mueckler (40) 2005; 280 Yoshimura (2) 2009; 2 Meric-Bernstam (30) 2004; 10 Roman (44) 2006; 5 Iglehart (45) 2007; 138 Guan (19) 2006; 126 Sabatini (12) 2012; 149 Coleman (29) 2001; 276 Nie (1) 2007; 26 Sabatini (18) 2005; 307 Bornfeldt (28) 2007; 56 Henske (32) 2006; 355 |
References_xml | – volume: 355 start-page: 1345 year: 2006 ident: 32 article-title: The tuberous sclerosis complex publication-title: N Engl J Med doi: 10.1056/NEJMra055323 contributor: fullname: Henske – volume: 138 start-page: 37 year: 2007 ident: 45 article-title: Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells publication-title: J Surg Res doi: 10.1016/j.jss.2006.07.003 contributor: fullname: Iglehart – volume: 29 start-page: 95 year: 2004 ident: 20 article-title: The glamour and gloom of glycogen synthase kinase-3 publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2003.12.004 contributor: fullname: Johnson – volume: 52 start-page: 1936 year: 2011 ident: 47 article-title: Tyrosine phosphatase SHP2 regulates the expression of acyl-CoA synthetase ACSL4 publication-title: J Lipid Res doi: 10.1194/jlr.M015552 contributor: fullname: Cornejo Maciel – volume: 2 start-page: 527 year: 2009 ident: 2 article-title: Arachidonic acid pathway: A molecular target in human testicular cancer (Review) publication-title: Mol Med Rep doi: 10.3892/mmr_00000131 contributor: fullname: Yoshimura – volume: 2 start-page: 10 year: 2003 ident: 3 article-title: Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer publication-title: Mol Cancer doi: 10.1186/1476-4598-2-10 contributor: fullname: Adrian – volume: 26 start-page: 525 year: 2007 ident: 1 article-title: Cyclooxygenases, prostanoids, and tumor progression publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-007-9096-5 contributor: fullname: Nie – volume: 276 start-page: 24667 year: 2001 ident: 29 article-title: Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones publication-title: J Biol Chem doi: 10.1074/jbc.M010793200 contributor: fullname: Coleman – volume: 149 start-page: 274 year: 2012 ident: 12 article-title: mTOR signaling in growth control and disease publication-title: Cell doi: 10.1016/j.cell.2012.03.017 contributor: fullname: Sabatini – volume: 10 start-page: 307 year: 2009 ident: 13 article-title: Molecular mechanisms of mTOR-mediated translational control publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm2672 contributor: fullname: Blenis – volume: 10 year: 2013 ident: 10 article-title: Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer publication-title: PLoS One contributor: fullname: Monaco – volume: 34 start-page: 2785 year: 2014 ident: 39 article-title: dAcsl, the Drosophila ortholog of acyl-CoA synthetase long-chain family member 3 and 4, inhibits synapse growth by attenuating bone morphogenetic protein signaling via endocytic recycling publication-title: J Neurosci doi: 10.1523/JNEUROSCI.3547-13.2014 contributor: fullname: Zhang – volume: 19 start-page: 6680 year: 2000 ident: 26 article-title: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy publication-title: Oncogene doi: 10.1038/sj.onc.1204091 contributor: fullname: Rowinsky – volume: 98 start-page: 10031 year: 2001 ident: 27 article-title: Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cellsand publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.191379498 contributor: fullname: Kohn – volume: 5 start-page: 430 year: 2006 ident: 44 article-title: Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-05-0347 contributor: fullname: Roman – volume: 353 start-page: 259 year: 2011 ident: 38 article-title: Drosophila long-chain acyl-CoA synthetase acts like a gap gene in embryonic segmentation publication-title: Dev Biol doi: 10.1016/j.ydbio.2011.02.030 contributor: fullname: Wang – volume: 359 start-page: 1 year: 2001 ident: 21 article-title: GSK3 takes centre stage more than 20 years after its discovery publication-title: Biochem J doi: 10.1042/bj3590001 contributor: fullname: Cohen – volume: 21 start-page: 8671 year: 2001 ident: 14 article-title: Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation publication-title: Mol Cell Biol doi: 10.1128/MCB.21.24.8671-8683.2001 contributor: fullname: Meyuhas – volume: 10 start-page: 1013 year: 2004 ident: 30 article-title: Determinants of rapamycin sensitivity in breast cancer cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-03-0043 contributor: fullname: Meric-Bernstam – volume: 30 start-page: 214 year: 2008 ident: 16 article-title: AMPK phosphorylation of raptor mediates a metabolic checkpoint publication-title: Mol Cell doi: 10.1016/j.molcel.2008.03.003 contributor: fullname: Shaw – volume: 94 start-page: 421 year: 2003 ident: 8 article-title: Fatty acid-CoA ligase 4 is overexpressed in human hepatocellular carcinoma publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2003.tb01458.x contributor: fullname: Kim – volume: 281 start-page: 39128 year: 2006 ident: 34 article-title: Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1 publication-title: J Biol Chem doi: 10.1074/jbc.M610023200 contributor: fullname: Kimball – volume: 280 start-page: 40406 year: 2005 ident: 40 article-title: mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes publication-title: J Biol Chem doi: 10.1074/jbc.M508361200 contributor: fullname: Mueckler – volume: 26 start-page: 63 year: 2006 ident: 23 article-title: Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation publication-title: Mol Cell Biol doi: 10.1128/MCB.26.1.63-76.2006 contributor: fullname: Kandror – volume: 61 start-page: 8429 year: 2001 ident: 7 article-title: Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma publication-title: Cancer Res contributor: fullname: Prescott – volume: 166 start-page: 213 year: 2004 ident: 22 article-title: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins publication-title: J Cell Biol doi: 10.1083/jcb.200403069 contributor: fullname: Lamb – volume: 307 start-page: 1098 year: 2005 ident: 18 article-title: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex publication-title: Science doi: 10.1126/science.1106148 contributor: fullname: Sabatini – volume: 16 start-page: 4572 year: 2005 ident: 41 article-title: TOR complex 2 integrates cell movement during chemotaxis and signal relay in Dictyostelium publication-title: Mol Biol Cell doi: 10.1091/mbc.e05-04-0342 contributor: fullname: Firtel – volume: 25 start-page: 6373 year: 2006 ident: 33 article-title: Stress and mTORture signaling publication-title: Oncogene doi: 10.1038/sj.onc.1209889 contributor: fullname: Sabatini – ident: 11 – volume: 27 start-page: 635 year: 2013 ident: 37 article-title: Long-chain Acyl-CoA synthetase 4A regulates Smad activity and dorsoventral patterning in the zebrafish embryo publication-title: Dev Cell doi: 10.1016/j.devcel.2013.11.011 contributor: fullname: Farber – volume: 29 start-page: 3733 year: 2010 ident: 17 article-title: Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy publication-title: Oncogene doi: 10.1038/onc.2010.139 contributor: fullname: Guertin – volume: 8 start-page: 387 year: 2008 ident: 36 article-title: Wnt signalling and its impact on development and cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc2389 contributor: fullname: Birchmeier – volume: 32 start-page: 160 year: 2013 ident: 42 article-title: Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis publication-title: Oncogene doi: 10.1038/onc.2012.47 contributor: fullname: Bai – volume: 10 start-page: 735 year: 2010 ident: 24 article-title: Focal adhesion kinase as a cancer therapy target publication-title: Anticancer Agents Med Chem doi: 10.2174/187152010794728648 contributor: fullname: Golubovskaya – volume: 7 start-page: e40794 year: 2012 ident: 4 article-title: The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target publication-title: PLoS One doi: 10.1371/journal.pone.0040794 contributor: fullname: Podesta – volume: 4 ident: 35 article-title: Wnt signaling in cancer publication-title: Cold Spring Harb Perspect Biol contributor: fullname: Polakis – volume: 314 start-page: 3340 year: 2008 ident: 43 article-title: Arachidonic acid promotes FAK activation and migration in MDA-MB-231 breast cancer cells publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2008.08.018 contributor: fullname: Salazar – volume: 3 start-page: 91 year: 2010 ident: 9 article-title: Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity publication-title: Transl Oncol doi: 10.1593/tlo.09202 contributor: fullname: Stafforini – volume: 8 start-page: 896 year: 2010 ident: 15 article-title: Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-09-0409 contributor: fullname: Sarbassov dos – volume: 5 start-page: e15540 year: 2010 ident: 6 article-title: Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells publication-title: PLoS One doi: 10.1371/journal.pone.0015540 contributor: fullname: Podesta – ident: 46 – volume: 8 start-page: e77060 year: 2013 ident: 5 article-title: Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer publication-title: PLoS One doi: 10.1371/journal.pone.0077060 contributor: fullname: Monaco – volume: 56 start-page: 1143 year: 2007 ident: 28 article-title: Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages publication-title: Diabetes doi: 10.2337/db06-0267 contributor: fullname: Bornfeldt – ident: 25 – volume: 126 start-page: 955 year: 2006 ident: 19 article-title: TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth publication-title: Cell doi: 10.1016/j.cell.2006.06.055 contributor: fullname: Guan – volume: 99 start-page: 1992 year: 2008 ident: 31 article-title: mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels publication-title: Cancer Sci contributor: fullname: Cohen |
SSID | ssj0000547829 |
Score | 2.3601472 |
Snippet | Although the role of acyl-CoA synthetase 4 (ACSL4) in mediating an aggressive phenotype is well accepted, there is little evidence as to the early steps... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 42632 |
SubjectTerms | Animals Blotting, Western Breast Neoplasms - metabolism Cell Line, Tumor Coenzyme A Ligases - metabolism Drug Resistance, Neoplasm - physiology Female Gene Expression Regulation, Neoplastic Heterografts Humans Mice Mice, Nude Receptors, Estrogen - metabolism Research Paper Signal Transduction - physiology TOR Serine-Threonine Kinases - metabolism Transfection |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NT9wwELUoXHqpivq1pSBX6qVSTdefiQ8IrRAIVSpIFStxi2yvXZCoA9lQdf9Sf2VnksCyLYdeY2cS5dmZN_LzMyEfoD6LYxES4z4JphJPzFthmHYmFcYFWbhO5Xtijqfqy7k-X26PHj7g_NHSDs-TmjZXu79uFvsw4fdwwpdGis81-hh0wuldDQnvCdkQkBdR4PV1IPu907eCdGiHtcrHblzNTf8Qzr91kw8S0dFz8mxgkHTSQ75J1mJ-QX5PwuKKHdQTOl9k4HQtJCemPlFHgTbTpj9wvm5oneiPs9Nv1OUZtF3XLYqFINqDbVi0f1UKbJbGfNEpBCi8YFPDWINQqIOBJkyICCq9XF5kvQTsZ-zisxy_d7bi1KPyvaUBYzUvyfTo8OzgmA3HMLAgrWmZdbPoVUhqZksDf0PhlYfCGbkAdxYY5oxLFbzm0ox9KEOyURTeBM3LJGzJ5Suynusc3xAqZAQ-EH2hY6mglvHSRC6dVgl5qy9G5OMdANV177ZRYZWCYFVLsCoEa0Te3yFUwZTAdQ6XY307r4ARoW-blNDndY_YfTRhtISKbTwixQqW9x3Qbnu1JV9edLbbCn2PtH37H8_dIk-BWGmUvXD9jqy3zW3cBvLS-p1uTP4B-ML3Sw priority: 102 providerName: Scholars Portal |
Title | Acyl-CoA synthetase-4, a new regulator of mTOR and a potential therapeutic target for enhanced estrogen receptor function in receptor-positive and -negative breast cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26536660 https://search.proquest.com/docview/1754085332 https://pubmed.ncbi.nlm.nih.gov/PMC4767459 |
Volume | 6 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEBXZnHopLf3apg0q9FKodiPrw9ZxWZqGQtpSEtibkbRSs5CVF8cJ5C_lV3ZGXieb9taLD5Y8CN7Y8wY_PRHyEfqzcFT4yLiLBZORR-ZMoZmyOpbaelHarPL9rk_O5beFWuwRNeyFyaJ971aTdLmepNVF1lZu1n466MSmP0_nEh1olJmOyAjK706L3ht6S6h6ZvtLstKimDboc5CF1RMFBRENgLUSuvel3KlG_1DMv5WSO6Xn-Bl5uuWMdNav7TnZC-kFuZv520s2b2b06jYBi-ugHDH5mVoKRJm2_RHzTUubSNdnP35Rm5Ywtmk6lAdBtJ2NV7RfNQX-SkO6yJoACgtsG8guCIXKFxjCEogw0tXDTdaLvm5Cjs9S-J2NxKlDrXtHPcZqX5Lz4y9n8xO2PXiBeWF0x4xdBid9lEtTafj-FU46aJWx-nNrgFMuuZDeKS70kfOVjyYUpdNe8SoWpuLiFdlPTQpvCC1EAAYQXKlCJaF7cUIHLqySEZmqK8fk0wBAven9NWrsSxC3-gG3GnEbkw8DQjW8BPhnw6bQXF_VwIHQqU0ImPO6R-w-2gD1mJSPsLyfgAbbj0cg77LR9jbP3v73kwfkCRAshfIXrt6R_a69Du-BxHTukIy-LjhcT2V1mBP4D0c_-08 |
link.rule.ids | 230,314,727,780,784,885,2221,24318,27924,27925,53791,53793 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKOcAFteJroYCRuCDh3Tr-SHxcragWaAtCW6m3yPbadKWus0rTSv1L_ZXMJJt2W25cY2dk6U0yb-TnZ0I-QX8W9jMfGXcxYzLyyJzJNFNWx1xbL3LbqnyP9fREfj9Vp1tE9WdhWtG-d4thOl8O0-Ks1Vauln7U68RGv44mEh1olBk9Io-VyA3faNI7S28Jdc-sNyULLbJRhU4HrbR6qKAkogWwVkJ3zpQb9egfkvlQK7lRfA52yLM1a6TjbnW7ZCuk5-Rm7K_P2aQa04vrBDyugYLE5BdqKVBlWneXzFc1rSJdzn7-pjbNYWxVNSgQgmgbR69ot2oKDJaGdNaqAigssK4gvyAUal9gCIsgAkkXdw9ZJ_u6Cm18lsKf1kqcOlS7N9RjrPoFOTn4OptM2frqBeaF0Q0zdh6c9FHOTaHhD5g56aBZxvrPrQFWOedCeqe40PvOFz6akOVOe8WLmJmCi5dkO1UpvCY0EwE4QHC5CoWE_sUJHbiwSkbkqi4fkM89AOWqc9gosTNB3Mo73ErEbUA-9giV8Bng3oZNobq8KIEFoVebEDDnVYfYbbQe6gHJ72F5OwEttu-PQOa1VtvrTHvz329-IE-ms6PD8vDb8Y-35CnQLYViGK72yHZTX4Z3QGka975N4L_IY_zZ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LatwwFBVtCqWb0tLX9KlCN4VqHFkP28th2iF9paEkkJ2RZCkZyMiD4xTyS_3K3ivPJE6769aSL4Jz7XsuOjoi5B30Z343d4FxG3ImAw_MVrlmyuhQaONEYZLKd1_vHckvx-p4dNVXEu07u5zGs9U0Lk-TtnK9ctlWJ5YdfJ9LdKBRVbZuQnab3FECkmzUqA-23hJqX7XZmCy1yLMW3Q6SvHqqoCyiDbBWQg_ulKOa9A_R_FsvOSpAiwfk_oY50tmwwofklo-PyO-Zuzxj83ZGzy8jcLkeihKTH6ihQJdpN1w033a0DXR1-OMnNbGBsXXbo0gIoo2OX9Fh1RRYLPXxNCkDKCywayHHIBTqX2AICyGCSZfXD9kg_frlU3wW_UmyE6cWFe89dRire0yOFp8O53tsc_0Cc6LSPatM4610QTZVqeEvmFtpoWFGDsBNBcyy4UI6q7jQu9aVLlQ-L6x2ipchr0ounpCd2Eb_jNBceOAB3hbKlxJ6GCu058IoGZCv2mJC3m8BqNeDy0aN3QniVl_jViNuE_J2i1ANnwLub5jo24vzGpgQ-rUJAXOeDohdRdtCPSHFDSyvJqDN9s0RyL5kt73Jtuf__eYbcvfg46L-9nn_6wtyDxiXQj0MVy_JTt9d-FfAanr7OuXvH01e_ew |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acyl-CoA+synthetase-4%2C+a+new+regulator+of+mTOR+and+a+potential+therapeutic+target+for+enhanced+estrogen+receptor+function+in+receptor-positive+and+-negative+breast+cancer&rft.jtitle=Oncotarget&rft.au=Orlando%2C+Ulises+D&rft.au=Castillo%2C+Ana+F&rft.au=Dattilo%2C+Melina+A&rft.au=Solano%2C+Angela+R&rft.date=2015-12-15&rft.eissn=1949-2553&rft.volume=6&rft.issue=40&rft.spage=42632&rft.epage=42650&rft_id=info:doi/10.18632%2Foncotarget.5822&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon |